Compare Campbell Soup Co. (CPB) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Campbell Soup Co. vs IDEXX Laboratories, Inc. — how do they compare? Campbell Soup Co. trades at $19.21 (market cap $5.78B), while IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is far larger — about 7× Campbell Soup Co.'s market cap, and Campbell Soup Co. pays a 5.16% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Campbell Soup Co. for 98 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| CPB | IDXX | |
|---|---|---|
Market Cap | $5.78B | $40.43B |
Volume | 11,705,427 | 692,164 |
Sector | Consumer Staples | Health |
52-Week High | $31.66 | $766.68 |
52-Week Low | $18.90 | $504.70 |
Typical Hold Time | 98 Days | 46 Days |
Enterprise Value | $12.83B | $41.32B |
Dividend Yield | 5.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Campbell's (CPB) trades at $19.37, up 2.49% today, but faces significant headwinds with a recent 36% dividend cut and bearish technical signals. The stock shows mixed earnings performance with two recent beats but a Q4 2026 miss, while fundamentals reveal modest revenue growth to $10.25B but declining net margins to 4.14%. Analyst sentiment remains cautious with only 3.45% buy ratings amid ongoing restructuring efforts.
The outlook remains challenging with weak FY2027 guidance and margin pressure, though current valuation (P/E 14.79) may attract value investors. Key risks include execution of $500M cost savings plan, competitive pressures, and consumer spending trends. The dividend yield near 5% post-cut offers income potential but requires careful monitoring of cash flow sustainability.
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
